Shire has agreed to a written request by the FDA to conduct pediatric clinical studies to investigate the potential use of lisdexamfetamine dimesylate to treat ADHD in preschool-age children, aged four to five years.

READ FULL ARTICLE Curated publisher From Pharmaceutical Business Review